AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.
Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.
ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...
Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).
The US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate (ADC) later this year.
CDMO Sterling Pharma Solutions has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...
BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.
The US biotech CytomX has lost a collaboration partner as AbbVie pulled out of a collaboration developing an antibody-drug conjugate (ADC) for the treatment of solid tumours.
In acquiring antibody-drug conjugates technology pioneer Seagen, Pfizer eyes up the strong growth trajectories of Seagen's medicines and the potential of its pipeline and technology.
The South Korean player plans to expand its recently acquired US facility, to provide contract manufacturing services for Antibody Drug Conjugates (ADC), and to add drug product fill & finish facilities to establish a foothold in the North American...
NextCure and LegoChem Biosciences have announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
IGM Biosciences is teaming up with ADC Therapeutics on a clinical trial collaboration and supply agreement to assess the combination of an IgM antibody and an ADC for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma...
Antibody-drug conjugate developer, Synaffix, has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr metal-free click chemistry.
iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics.
Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.
The antibody drug conjugate market has had a busy few years, as the appetite for acquisitions of ADC-specialists began to grow, with Gilead buying Immunomedics and Merck acquiring VelosBio.
Merck has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin, US.
Bionova Scientific, a US biologics CDMO, is to be acquired by the US arm of Asahi Kasei Medical, part of the Asahi Kasei Group, owned by Tokyo based Asahi Kasei Corporation.
CDMO Piramal Pharma Solutions will expand capabilities of its Antibody-Drug Conjugate (ADC) facility in Grangemouth, Scotland; and invest in new Active Pharmaceutical Ingredient (API) infrastructure at its Morpeth, England facility.
Novasep has signed a manufacturing services agreement with Exelixis, an oncology-focused US biotechnology company, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC).
Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced...
UK-based biotechnology company, Iksuda Therapeutics, has completed a US$47m (£34m) financing round, which was led by Mirae Asset financial group and included a strategic investment from Korean biopharma player, Celltrion.
Data management in antibody drug conjugate (ADC) manufacturing is challenging says ADC/Labs, which is trying to help scientists in the field get around such obstacles.
The US Food and Drug Administration (FDA) has approved ADC Therapeutics’ ZYNLONTA as a third-line therapy for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), has acquired ADC Biotechnology (ADC Bio), a UK based company specializing in antibody-drug conjugates (ADCs).
UK company, Spirea, a spin-out from the University of Cambridge, which was founded to deliver the next generation of antibody drug conjugate (ADC) cancer therapeutics, has secured financing from o2h Ventures and Syndicate Room.
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
Lonza already manufacturers three out of five commercially available ADCs but is preparing for additional demand with a two-year expansion project at its Visp site.
WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.
Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.